Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Besifovir - IlDong Pharmaceuticals/LG Chem

Drug Profile

Besifovir - IlDong Pharmaceuticals/LG Chem

Alternative Names: ANA-380; Besifovir dipivoxil; Besivo; LB-80380

Latest Information Update: 28 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LG Life Sciences
  • Developer Ildong Pharmaceutical; LG Life Sciences
  • Class Antivirals; Hypoxanthines; Phosphonic acids; Purine nucleotides; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Hepatitis B virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 13 Jan 2019 Launched for Hepatitis B (Monotherapy, Treatment-resistant) in South Korea (PO) (NCT03885778) before January 2019
  • 13 Jan 2019 Launched for Hepatitis B (Treatment-naive) in South Korea (PO) (NCT03885778) before January 2019
  • 20 Aug 2015 No recent reports on development identified - Phase-II for Hepatitis B (Treatment-naive) in Hong Kong (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top